Ernst emphasized the strategic transformation of Tivic into a diversified therapeutics company, combining biologic and bioelectronic approaches to address immune dysregulation. This includes ...

Biofrontera Inc. reports a record $37.3M in 2024 revenue, FDA milestones, and strategic growth plans for 2025.

Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...

This approval, based on the HELIOS-B Phase 3 clinical trial results, signifies AMVUTTRA as the first and only FDA-approved therapy ... in its impressive 85.62% gross profit margin and healthy ...

Scpharmaceuticals (($SCPH)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for ...

Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ ... Morgan Stanley estimates a gross-to-net discount of around 23%, which would create a net pricing tailwind ...

(Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth ...

scPharmaceuticals reported Q4 2024 revenue of $12.2 million, FDA approved FUROSCIX for chronic ... 41,000 FUROSCIX doses filled in 2024 Gross-to-net (GTN) discount of 19% and 16% for the fourth ...

Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc.

DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...